Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19788602 | 0.85 | TSHR (0.31) | TSHRCYP3A4 | |
| SCHEMBL21470017 | 0.81 | HPGD (0.34) | TSHR | |
| SCHEMBL23569446 | 0.80 | TSHR (0.36) | TSHRHSD11B1CYP3A4GABRA1GABRB2 | |
| SCHEMBL11161495 | 0.74 | TSHR (0.37) | TSHRHSD11B1CYP3A4GABRA1GABRB2 | |
| SCHEMBL22858362 | 0.73 | LMNA (0.52) | TSHRCYP3A4 | |
| SCHEMBL21892002 | 0.72 | CYP2C19 (0.57) | ABCB1 | |
| SCHEMBL19504212 | 0.70 | — | — | |
| SCHEMBL21470027 | 0.70 | HPGD (0.33) | TSHR | |
| SCHEMBL18264956 | 0.69 | CYP3A4 (0.39) | TSHRHSD11B1CYP3A4ABCB1 | |
| SCHEMBL14871776 | 0.68 | CYP3A4 (0.32) | TSHRHSD11B1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220195348-A1 | TREATMENT COMPOSITIONS COMPRISING PLANT ROSIN MATERIAL AND CERTAIN PERFUME RAW MATERIALS | THE PROCTER & GAMBLE COMPANY | 2022-06-23 | — | — | US | disclosed |
| EP-3793514-B1 | FRAGRANCE COMPOSITIONS | GIVAUDAN SA (CH) | 2022-04-20 | — | — | EP | disclosed |
| US-20210045985-A1 | ORGANIC COMPOUNDS | GIVAUDAN S.A. (CH) | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210045985-A1 | ORGANIC COMPOUNDS | OR51E2, OR10J3, ELOC | TSHR 4786/4885HSD11B1 1213/4885CYP3A4 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.